Senseonics Reports Strong Financials and Strategic Plans
Senseonics Holdings, Inc. (NYSE American: SENS), a pioneering medical technology firm, has shared its preliminary unaudited revenue figures for the third quarter of the year. The company recorded an impressive revenue of approximately $8.1 million, representing a remarkable 91% increase compared to the same period last year. This surge is primarily attributed to a significant boost in new patient starts, which soared by around 160% within the U.S.
Record New Patient Engagement
Driving this growth, Senseonics has ramped up its direct-to-consumer (DTC) marketing initiatives, resulting in the highest monthly new patient starts in the company's history in September. This strategic move has effectively heightened awareness of the Eversense CGM systems among potential patients and healthcare providers, leading to a remarkable acceleration in patient engagement.
Preparing for a Reverse Stock Split
In alignment with its growth strategy, Senseonics has also announced plans for a reverse stock split at a ratio of 1-for-20. This will reduce the number of shares outstanding from approximately 816 million to about 41 million. The split is set to become effective at 5:00 p.m. Eastern Time, aiming to enhance the company's stock appeal and improve its market performance.
CEO Comments on Company Momentum
Tim Goodnow, the President and CEO, expressed his enthusiasm about the company's performance, highlighting the strong demand for Eversense 365, a long-term continuous glucose monitoring solution designed for patients managing diabetes. He noted the positive impact of the DTC campaigns and the internalization of sales and marketing operations, which he believes will allow Senseonics to better meet patient needs and drive further revenue growth.
Details on Reverse Stock Split Effects
The reverse stock split, approved by stockholders, will affect all outstanding shares and will not change ownership percentages significantly. However, it may cause a few minor adjustments due to cash payments replacing fractional shares. Stockholders will receive updates regarding their holdings from the company’s transfer agent, ensuring a smooth transition for investors.
Innovative Technologies from Senseonics
Senseonics is dedicated to transforming diabetes management through innovative technology. The company’s flagship Eversense systems offer unique features, including a small sensor that is completely implanted under the skin and communicates glucose readings directly to a smart device. This real-time monitoring enables patients to manage their blood glucose levels more effectively, improving their quality of life.
Market Positioning and Future Outlook
The Eversense systems are designed for long-term use, with the Eversense 365 capable of operating for up to a year, providing a replacement option for traditional fingerstick measurements. These advancements in diabetes management position Senseonics favorably within a competitive market, enhancing its potential for growth.
Frequently Asked Questions
What was Senseonics' revenue in Q3 2025?
Senseonics reported a preliminary revenue of approximately $8.1 million for Q3 2025.
What is a reverse stock split?
A reverse stock split is a reduction in the number of a company's outstanding shares, intended to increase the per-share price and enhance the stock's marketability.
How many new patients did Senseonics gain in Q3 2025?
The company experienced a 160% increase in new patient starts compared to the previous year.
What is the Eversense system?
The Eversense system is a long-term continuous glucose monitoring solution that provides real-time glucose data and is implanted under the skin.
How will stockholders be informed about the changes from the reverse stock split?
Stockholders will receive information from the company's transfer agent regarding their holdings and any cash payments due to fractional shares following the reverse stock split.
